

Announcement for Rhodimet A-Dry+® a new Powder Methionine product

Adisseo announces today the development of its truly innovative product Rhodimet A-Dry+®. It is a brand new powder methionine product, based on the liquid methionine (“HMTBA”) technology, in order to offer the advantages of this molecule to customers whose manufacturing process does not allow the use of liquid form.

I. General introduction of the product

Based on a patented technology and with the support of its formulation expert subsidiary, Adisseo has developed a unique process, which allows to get premium quality powder at 88% potency. Additional benefits such as improved anti-oxidation and anti-microbial effects will also be available to powder users. The mechanical characteristics, flowability and homogeneity in particular, of Rhodimet A-Dry+® are optimized to match best-in-class in the market enabling superior performance in mixability, a key criteria for powder users.

Rhodimet A-Dry+® is expected to be launched in the market early 2018. A new production unit implementing this new technology is currently being built on the Burgos site in Spain and expected to be commissioned by the end 2017. Its design has integrated the full value of Sustainable Development and the project has involved significant expertise from the Company in order to get minimal impact to the environment.

II. Impact on the Company

The Rhodimet A-Dry+® could further reinforce Adisseo’s leadership role in methionine market. For all customers already fully convinced about the HMTBA benefits, Adisseo will provide two products with same specifications (88% potency) either in powder (Rhodimet A-Dry+®) or in liquid (Rhodimet AT88®) form, allowing them to use it and get the HMTBA’s benefits in all their facilities: Premix, Concentrates or Feed.

III. Risk reminder

Adisseo remind the investors, this product is expected to be launched in the market early 2018. For the risk factors related to the methionine products, please refer to 2015 annual report, section IV, paragraph III, article 4 Possible risks in the future. Please take care of investment risk.